Business Wire

Seagen to Highlight Research in Urothelial and Colorectal Cancers at 2022 European Society for Medical Oncology (ESMO) Congress


Seagen Inc. (Nasdaq:SGEN) today announced upcoming presentations of new data from its clinical development programs at the European Society for Medical Oncology (ESMO) Congress 2022, to be held September 9-13 in Paris, France. One of two late-breaking oral presentations will feature results from Cohort K of EV-103 (also known as KEYNOTE-869), a phase 1b/2 clinical trial conducted in partnership with Astellas. Cohort K is evaluating PADCEV® (enfortumab vedotin-ejfv) as monotherapy or in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible to receive cisplatin-based chemotherapy. Merck is known as MSD outside the United States and Canada.

A second late-breaking oral presentation will include additional results from the phase 2 MOUNTAINEER trial evaluating TUKYSA® (tucatinib) in combination with trastuzumab in patients with previously treated HER2-positive metastatic colorectal cancer (mCRC). Patient-reported outcomes from MOUNTAINEER also will be detailed in a separate presentation. Data from the MOUNTAINEER trial formed the basis of a supplemental New Drug Application submitted to the U.S. Food and Drug Administration (FDA) under the Accelerated Approval Program. On July 28, 2022, the FDA granted Breakthrough Therapy Designation for tucatinib in combination with trastuzumab for the treatment of adult patients with unresectable or metastatic HER2-positive CRC who have previously received fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy. The designation is based on results from the MOUNTAINEER trial.

“These important data to be shared at the ESMO Congress reflect our commitment to develop innovative solutions for patients with challenging clinical needs in cancer,” said Marjorie Green, M.D., Senior Vice President and Head of Late-Stage Development at Seagen.

Presentations of Company-Sponsored Trials





PADCEV® (enfortumab vedotin-ejfv)

Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)


Oral Presentation / Proffered Paper Session 2: GU Tumours, Non-prostate, September 12,

14:55-15:05 CEST

J. Rosenberg

TUKYSA® (tucatinib)

Additional analyses of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC


Mini Oral Presentation / Mini Oral Session: GI, Lower Digestive, September 12, 14:50-14:55 CEST

J. H. Strickler

Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph 2 study MOUNTAINEER​


Poster Session 7, September 11, 12:00-13:00 CEST

C. Wu

TUKYSA® (tucatinib) Trials in Progress

MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer (trial in progress)


Poster Session 8, September 11, 12:00-13:00 CEST 

T. André 

Disitamab vedotin Trials in Progress

Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001, trial in progress)


Poster Session 12, September 12, 12:00-13:00 CEST

V. S. Koshkin

Health Economics and Outcomes Research

Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer (HER2+ mCRC): A systematic literature review and meta-analysis of clinical outcomes


 Poster Session 8, September 11, 12:00-13:00 CEST

T. S. Bekaii-Saab 

About Seagen

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on our marketed products and robust pipeline, visit and follow @SeagenGlobal on Twitter.

Forward-Looking Statements

Certain statements made in this press release are forward looking, such as those, among others, relating to the therapeutic potential of PADCEV, TUKYSA, disitamab vedotin and the company’s other products and product candidates, including their potential efficacy, safety and therapeutic uses, and the potential for TUKYSA to receive accelerated approval from the FDA based on data from the MOUNTAINEER trial. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the possibility that data from the MOUNTAINEER trial and other trials may not be sufficient to support any regulatory approvals; the risk of adverse events, including the potential for newly-emerging safety signals; adverse regulatory actions; delays, setbacks or failures in clinical development activities, the submission of regulatory applications and the regulatory review process for a variety of reasons, including the difficulty and uncertainty of pharmaceutical product development. More information about the risks and uncertainties faced by Seagen is contained under the caption “Risk Factors” included in the company’s Quarterly Report on Form 10-Q for the year ended June 30, 2022 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

To view this piece of content from, please give your consent at the top of this page.

Contact information

For Media
David Caouette
(310) 430-3476

For Investors
Douglas Maffei, Ph.D.
(425) 527-4881

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

S64 Bolsters Pioneering Team With Strategic Hires Amid Surging Demand for Private Markets Products29.9.2022 14:05:00 CEST | Press release

S64, the trusted alternatives partner to the world’s leading asset managers and private banks, has today announced a series of strategic hires following a period of rapid growth since its launch in 2020. S64’s best-in-class team, who worked together for over a decade at Deutsche Bank, has further strengthened its expertise by making a number of appointments from blue-chip institutions to its London office. The business also has plans to advance its footprint across EMEA, Asia and Australia in major global financial hubs. Strategic hires following rapid growth Led by founder and CEO Tarun Nagpal, S64’s team has led the way in industry innovation for more than a decade, pioneering the development of alternative platform solutions. The latest additions include Venkata Kota, Head of Client Solutions, formerly of Goldman Sachs and Deutsche Bank; Richard Marland, Head of Operations and Fund Governance, formerly of Deutsche Bank; Tetyana Turek, Business and Project Management, formerly of Deu

Strengthening Healthcare Systems to Meet Patients’ Need for Plasma-Derived Therapies29.9.2022 14:00:00 CEST | Press release

As part of their well-established partnership, the United Nations Institute for Training and Research (UNITAR) and Takeda (TSE:4502/NYSE:TAK), a global pharmaceutical leader and an active member of the United Nations Global Compact, are pleased to announce a new joint initiative focused on strengthening countries’ healthcare systems to meet patients’ need for plasma and plasma-derived therapies. The initiative will draw on UNITAR’s expertise in training and education toward the development of innovative solutions to global challenges and Takeda’s deep knowledge of rare disease and the plasma ecosystem. Global demand for plasma has greatly increased over the past 20 years and is continuing to grow due to increasing numbers of patients with rare diseases being diagnosed, as well as higher standards of care and broader access to treatment globally. This demand for life-changing and life-sustaining plasma-derived therapies far exceeds available supply, resulting in more people around the w

Adrestia appoints Will Lewis as Chair, establishes US Operations and appoints new functional leads29.9.2022 13:00:00 CEST | Press release

Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced that it appointed William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors, Jennifer Millian, M.S., M.B.A. as VP of U.S. Operations, and Philip Coxon, Ph.D., as VP of Business Development. This extends Adrestia’s presence to the United States and deepens its drug development capabilities as it moves its emerging pipeline of first-in-class therapeutics towards the clinic. This press release features multimedia. View the full release here: Will Lewis, Adrestia Chairman “Adrestia’s leading synthetic rescue platform is systematically mining the human genome to find new ways of treating patients with currently intractable diseases” said Lewis. “The team unites world-class biology and drug discovery leadership with an exciting vision for genetic medicine. We are discovering new biology that opens fresh ways of thinking about ta

Fluor Selected for Expansion of Large-Scale Biologics Manufacturing Facility in Scandinavia29.9.2022 12:54:00 CEST | Press release

Fluor Corporation (NYSE: FLR) announced today that the company has been selected by a leading biologics company to perform procurement and construction management for a large-scale biologics drug substance manufacturing facility located in Scandinavia. Fluor will book the multi-hundred-million-dollar reimbursable contract value in the third quarter of 2022. The facility will produce new capacity for advanced biologics that are used in a variety of treatments including vaccines, oncology and quality-of-life medicines. Fluor has performed the planning and enabling work for this project, and construction is now underway with the facility scheduled to be operational by 2025. Fluor’s Advanced Technologies & Life Sciences business is leading the project including support from its Nordic Technology Hub in Copenhagen, Denmark. About Fluor Corporation Fluor Corporation (NYSE: FLR) is building a better future by applying world-class expertise to solve its clients’ greatest challenges. Fluor’s 41

Versace Chooses Board to Transform Retail Planning29.9.2022 12:22:00 CEST | Press release

Board, the leading global provider of Intelligent Planning Solutions which help organizations plan smarter — enabling actionable insights and better outcomes, today announced that Versace, the Italian fashion house that symbolizes luxury worldwide, has chosen Board to transform its Retail Planning. The Versace Group distributes its products through a direct network of over 200 owned boutiques and 1,500 distributors worldwide, with a turnover of more than one billion euros. Due to evolving challenges of global sourcing and the change in consumer purchasing habits, Versace recently revamped its retail strategy by opening new stores, strengthening their multi-channel approach and increasing investments in the efficiency of crucial business planning processes. "Board’s Intelligent Planning platform, provides the flexible and easy to use solutions necessary to support the innovation and growth of our brand,” said Francesco Loporcaro, IT Manager at Versace “Our selection of Board was influen